Contact Information: Contacts: Kevin Krenitsky Chief Executive Officer BioServe 301-470-3362 Constantine Theodoropulos Boston Communications 617-292-7319
BioServe Expands Into New Headquarters
| Source: BioServe
BELTSVILLE, MD--(Marketwire - August 27, 2007) - Reflecting BioServe's rapid emergence as a
preferred provider for processing, developing and validating diagnostic
tests, the company today announced its move to new corporate headquarters
in Beltsville, Maryland. The new 40,000 sq/ft. facility combines expanded
offices, state-of-the-art wet and dry laboratories and will also house the
Global Repository of over 600,000 DNA, tissue and
serum samples.
Over the past nine months BioServe has established itself as a company
offering a complete "biomaterial to validated data" genomics solution, and
is uniquely qualified to excel in the genomic diagnostics market.
BioServe's genomics solution enables partners to process vast amounts of
genomic material for testing, validate genetic test markers for new
diagnostics and develop new intellectual property underpinning the next
generation of molecular diagnostic tests.
Recent corporate highlights include:
-- The acquisition of Genomics Collaborative, a leader in facilitating
biomarker discovery and validation leveraging a comprehensive library
of 600,000 human DNA, tissue and serum samples
linked to detailed clinical and demographic data from 140,000 consented
and anonymized patients collected on four continents.
-- A landmark Public Health Study in partnership with Harvard and the
University of Michigan on a genetic study to understand the linkage
between lead exposure and children's intellectual development in India.
-- Selected by Suracell Inc. as its testing and technology partner to
build its personal genetic health and information technology
businesses.
-- Selected by Houston-based Specialized Clinical Center of Research
(SCCOR) for a novel study aimed at identifying the genetic cause of
thoracic aortic disease.
-- The development of a novel serum-based diagnostic test for the
identification of colorectal cancer (CRC), in collaboration with
Phenomenome Discoveries Inc.
"BioServe is a company growing and evolving at a tremendous pace. We are
excited to move into a world-class facility in the USA, which complements
our state-of-the-art facility in India. Our emergence into the rapidly
growing personalized and predictive diagnostics space, combined with our
comprehensive genomic services is creating a company uniquely positioned to
lead the burgeoning field of personalized medicine," said Kevin Krenitsky,
Chief Executive Officer, BioServe.
About BioServe
BioServe is a leader in the processing, development, and validation of
diagnostic tests for the practice of personalized, predictive and
preventive medicine including DNA methylation analysis services.
Leading pharma, biotech and diagnostic firms collaborate with BioServe to
identify and validate markers that cause disease while correlating clinical
and molecular data to develop new diagnostic tests promoting wellness
around the world. BioServe offers the Global Repository®, a growing tissue bank of over
600,000 human DNA, tissue and serum samples linked to detailed clinical
and demographic data from 140,000 consented and anonymized patients from
four continents. Leveraging BioServe's robust genomic analysis services, technology,
Global Repository and CLIA-certified laboratory, collaborators gain a
complete, highly efficient platform for processing diagnostic test results
and identifying genomic markers for powerful new assays. BioServe has
headquarters in Beltsville, MD and Hyderabad, India. For more information
please visit www.bioserve.com or call 301-470-3362.
All trademarks and registered trademarks are property of their respective
owners.